WT-2-2.0

WT-2-2.0 is a small molecule drug candidate currently in the preclinical stage of development, specifically in the lead selection and design phase. Developed by Hangzhou Westan Pharmaceutical Technology, the compound is designed to target the Transient Receptor Potential Vanilloid (TRPV) family of ion channels. TRPV channels are non-selective cation channels that play critical roles in sensory physiology, including the perception of pain, temperature, and chemical stimuli. While specific indications have not yet been disclosed, TRPV modulators are frequently investigated for the treatment of chronic pain, respiratory conditions, and inflammatory diseases.